As of the latest Form 4 filed Jun 2, 2026.
What Aurinia Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 24 most recent filings for AUPH.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | 2026-06-02 | TANG KEVIN Chief Executive Officer | PPurchase | +206K | $15.28 | $3.15M | No | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | TANG KEVIN, Chief Executive Officer | PPurchase | +99.00 | $15.34 | $1.52K | No | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | TANG KEVIN, Chief Executive Officer | PPurchase | +344K | $15.28 | $5.25M | No | Form 4 ↗ |
| 2026-06-02 | 2026-05-29 | TANG KEVIN, Chief Executive Officer | PPurchase | +263K | $15.31 | $4.02M | No | Form 4 ↗ |
| 2026-06-02 | 2026-05-29 | TANG KEVIN, Chief Executive Officer | PPurchase | +2.30K | $15.35 | $35.3K | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Cole Ryan Chief Operating Officer | AAward | +116K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Robertson Stephen P. Chief Legal Officer | AAward | +116K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Hearne Michael S Chief Financial Officer | AAward | +116K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Keenan Greg SVP, Chief Medical Officer | FTax | −8.07K | $14.32 | $116K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-03 | TANG KEVIN Director | PPurchase | +184K | $14.22 | $2.62M | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Miller Joseph M Chief Financial Officer | FTax | −37.5K | $14.21 | $533K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Donley Matthew Maxwell Chief Operating Officer | FTax | −40.8K | $14.21 | $579K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Greenleaf Peter Chief Executive Officer | FTax | −101K | $14.21 | $1.43M | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | Robertson Stephen P. EVP, General Counsel | FTax | −36.5K | $14.21 | $519K | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | TANG KEVIN Director | PPurchase | +116K | $14.21 | $1.65M | No | Form 4 ↗ |
| 2026-03-03 | 2026-03-02 | TANG KEVIN, Director | PPurchase | +83.6K | $14.33 | $1.20M | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Miller Joseph M Chief Financial Officer | AAward | +57.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Donley Matthew Maxwell Chief Operating Officer | AAward | +58.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Greenleaf Peter Chief Executive Officer | AAward | +196K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Keenan Greg SVP, Chief Medical Officer | AAward | +40.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | Robertson Stephen P. EVP, General Counsel | AAward | +59.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | TANG KEVIN Director | PPurchase | +1.60K | $14.38 | $23.0K | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | TANG KEVIN, Director | PPurchase | +215K | $14.12 | $3.03M | No | Form 4 ↗ |
| 2026-03-03 | 2026-02-27 | TANG KEVIN, Director | PPurchase | +300K | $13.90 | $4.17M | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also AUPH’s full analysis or the market-wide insider trading feed. The tabs above jump to AUPH’s other SEC data.
Source: SEC Form 4 filings for AUPH, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.